NDA 022016 · Cumberland Pharms
Vaprisol
Conivaptan Hydrochloride · Injection
Last checked: Nov 19, 2026Latest source record: Feb 28, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Feb 28, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
7 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VAPRISOL · CONIVAPTAN HYDROCHLORIDE 20MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Conivaptan" as an intervention, any sponsor and status, largest first.
- An Open-Label Study of YM087 (Conivaptan) in Patients With Euvolemic or Hypervolemic HyponatremiaPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00379847 · 251 participants · Start Feb 2004 · Primary completion Jun 2005
Drug: conivaptan · For: Hyponatremia
Sites: Tuscon, Arizona; Denver, Colorado; Washington D.C., District of Columbia · 28 sites in all
- Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart FailurePivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00057356 · 170 participants · Start Nov 2002 · Primary completion Mar 2004
Drug: conivaptan; placebo · For: Chronic Heart Failure
Sites: Huntsville, Alabama; Los Angeles, California; Manteca, California · 26 sites in all
- A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00435591 · 121 participants · Start Jan 2007 · Primary completion Sep 2008
Drug: Conivaptan; placebo · For: Hyponatremia; Euvolemia; Hypervolemia
Sites: Charleston, South Carolina; Bangalore, India; Bhopal, India · 18 sites in all
- Study of IV YM087 to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic HyponatremiaPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00380575 · 84 participants · Start Aug 2000
Drug: YM087 · For: Hyponatremia
Sites: Mobile, Alabama; Phoenix, Arizona; Tuscon, Arizona · 47 sites in all
- Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic HyponatremiaPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00492037 · 83 participants · Start Jan 2000
Drug: YM087 oral · For: Hyponatremia
Sites: Brussels, Belgium; Liège, Belgium; Tournai, Belgium · 29 sites in all
- Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic HyponatremiaPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00478192 · 50 participants · Start Apr 2007 · Primary completion Aug 2008
Drug: Conivaptan; Placebo · For: Hyponatremia
Sites: Huntsville, Alabama; Tucson, Arizona; Los Angeles, California · 26 sites in all
Cumberland PharmaceuticalsIndustry
NCT00851227 · 26 participants · Start Feb 2009 · Primary completion Jan 2010
Drug: conivaptan hydrochloride · For: Liver Disease; Hyponatremia
Sites: Miami, Florida
Cumberland PharmaceuticalsIndustry
NCT00887627 · 25 participants · Start Apr 2009 · Primary completion Jul 2010
Drug: conivaptan hydrochloride · For: Kidney Diseases; Hyponatremia
Sites: Anaheim, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetics of conivaptan use in patients with severe hepatic impairment.
Marbury T, Fox J, Kaelin B, et al. · Drug Des Devel Ther 2017 · Clinical Trial, Phase I
- Dose comparison of conivaptan (Vaprisol®) in patients with euvolemic or hypervolemic hyponatremia--efficacy, safety, and pharmacokinetics.
Palmer BF, Rock AD, Woodward EJ · Drug Des Devel Ther 2016 · Comparative Study, Controlled Clinical Trial
- Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.
Naidech AM, Paparello J, Liebling SM, et al. · Neurocrit Care 2010 · Comparative Study, Randomized Controlled Trial
- Vaptans for oedematous and hyponatraemic disorders in childhood: A systematic literature review.
Piffer A, Bianchetti MG, Leoni-Foglia C, et al. · Br J Clin Pharmacol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers.
Lasseter KC, Dilzer SC, Smith N · Adv Ther 2007 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage: A Safety and Tolerability Study.
Corry JJ, Asaithambi G, Shaik AM, et al. · Clin Drug Investig 2020 · Clinical Trial, Phase I
Sponsor: Cumberland Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.